Compile Data Set for Download or QSAR
Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 12748
TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724966(US12240825, Example 17)
Affinity DataKi:  0.794nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724950(US12240825, Example 1)
Affinity DataKi:  1nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724972(US12240825, Example 23)
Affinity DataKi:  1.26nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724968(US12240825, Example 19)
Affinity DataKi:  1.58nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724964(US12240825, Example 15)
Affinity DataKi:  2nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724967(US12240825, Example 18)
Affinity DataKi:  2.51nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724971(US12240825, Example 22)
Affinity DataKi:  3.16nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724954(US12240825, Example 5)
Affinity DataKi:  3.16nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724974(US12240825, Example 25)
Affinity DataKi:  3.16nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724969(US12240825, Example 20)
Affinity DataKi:  3.98nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724957(US12240825, Example 8)
Affinity DataKi:  3.98nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724963(US12240825, Example 14)
Affinity DataKi:  5.01nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724952(US12240825, Example 3)
Affinity DataKi:  5.01nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724973(US12240825, Example 24)
Affinity DataKi:  5.01nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724970(US12240825, Example 21)
Affinity DataKi:  6.31nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724961(US12240825, Example 12)
Affinity DataKi:  6.31nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724958(US12240825, Example 9)
Affinity DataKi:  6.31nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724956(US12240825, Example 7)
Affinity DataKi:  7.94nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724955(US12240825, Example 6)
Affinity DataKi:  7.94nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724959(US12240825, Example 10)
Affinity DataKi:  7.94nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724953(US12240825, Example 4)
Affinity DataKi:  10nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724960(US12240825, Example 11)
Affinity DataKi:  12.6nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724975(US12240825, Example 26)
Affinity DataKi:  12.6nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724962(US12240825, Example 13)
Affinity DataKi:  15.8nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724951(US12240825, Example 2)
Affinity DataKi:  20nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724965(US12240825, Example 16)
Affinity DataKi:  20nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724950(US12240825, Example 1)
Affinity DataKi:  50.1nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724967(US12240825, Example 18)
Affinity DataKi:  158nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724968(US12240825, Example 19)
Affinity DataKi:  251nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724973(US12240825, Example 24)
Affinity DataKi:  251nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724972(US12240825, Example 23)
Affinity DataKi:  316nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724961(US12240825, Example 12)
Affinity DataKi:  398nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724971(US12240825, Example 22)
Affinity DataKi:  501nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724964(US12240825, Example 15)
Affinity DataKi:  631nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724963(US12240825, Example 14)
Affinity DataKi:  1.00E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724962(US12240825, Example 13)
Affinity DataKi: >1.00E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724954(US12240825, Example 5)
Affinity DataKi:  1.00E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724953(US12240825, Example 4)
Affinity DataKi:  1.26E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724959(US12240825, Example 10)
Affinity DataKi: >1.26E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724958(US12240825, Example 9)
Affinity DataKi:  1.26E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724969(US12240825, Example 20)
Affinity DataKi:  1.59E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724960(US12240825, Example 11)
Affinity DataKi: >1.59E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724957(US12240825, Example 8)
Affinity DataKi:  1.59E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724970(US12240825, Example 21)
Affinity DataKi:  2.51E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724951(US12240825, Example 2)
Affinity DataKi:  2.51E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724974(US12240825, Example 25)
Affinity DataKi:  3.16E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724952(US12240825, Example 3)
Affinity DataKi:  3.98E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724966(US12240825, Example 17)
Affinity DataKi:  3.98E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724956(US12240825, Example 7)
Affinity DataKi: >5.01E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Nxera Pharma UK

US Patent
LigandPNGBDBM724955(US12240825, Example 6)
Affinity DataKi: >6.31E+3nMAssay Description:After thawing, membrane homogenates were resuspended in the binding buffer (8.5 mM HEPES, pH 7.4, 1.3 mM CaCl2, 1.2 mM MgSO4, 118 mM NaCl, 4.7 mM KCl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/4/2025
Entry Details
US Patent

Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: